home / news / Four-year EuroQol initiative to help accelerate COVID-19 related research ends

EuroQol sponsors ISPOR Europe 2024 symposium on using HRQoL data from children and youth to strengthen HTA: What are the challenges? How can we improve current practice?

Attending ISPOR Europe 2024 in Barcelona this month? Interested in...

Our Monthly Scientific Selection: October Publications on EuroQol Instruments #10

[1-31 October 2024] Stalmeier PFM, Roudijk B. What Makes the...

Call for Abstracts now open: 9th EuroQol Academy 2025 and 5th EuroQol Early Career Researcher Meeting 2025

Interested to participate in one of our annual meetings? The...

Our Monthly Scientific Selection: September Publications on EuroQol Instruments #9

[1-30 September 2024] Addo R, Mulhern B, Norman R, Owusu...

EQ-5D-Y-5L launched! A new EuroQol instrument providing children and adolescents with a wider range of options to describe their HRQoL

Launched as an approved EuroQol Group instrument today, the EQ-5D-Y-5L...

Four-year EuroQol initiative to help accelerate COVID-19 related research ends

Over the duration of the COVID-19 pandemic emergency, the EuroQol Research Foundation offered study-specific licenses free of charge to commercial customers wishing to use EQ-5D instruments in studies aimed at testing COVID-19 treatments or diagnostic tools. During this period, numerous commercial organisations undertook COVID-19 related research around the world using EQ-5D instruments – with EuroQol forgoing license fees equivalent to more than € 1 million. 

Now that a year has passed since the World Health Organisation determined that the COVID-19 pandemic no longer constitutes a public health emergency of international concern, the EuroQol Board has decided that the time is right to end our COVID-19 research support initiative. From the 1st December 2024, licensing of EQ-5D instruments for use in the COVID-19 related studies will be aligned with EuroQol’s standard licensing policy